GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » electroCore Inc (NAS:ECOR) » Definitions » Cash Conversion Cycle

ECOR (electroCore) Cash Conversion Cycle : 38.32 (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is electroCore Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

electroCore's Days Sales Outstanding for the three months ended in Dec. 2024 was 12.43.
electroCore's Days Inventory for the three months ended in Dec. 2024 was 166.71.
electroCore's Days Payable for the three months ended in Dec. 2024 was 140.82.
Therefore, electroCore's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2024 was 38.32.


electroCore Cash Conversion Cycle Historical Data

The historical data trend for electroCore's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

electroCore Cash Conversion Cycle Chart

electroCore Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only -537.59 -79.04 48.31 2.57 7.68

electroCore Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.96 19.34 78.86 86.42 38.32

Competitive Comparison of electroCore's Cash Conversion Cycle

For the Medical Devices subindustry, electroCore's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


electroCore's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, electroCore's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where electroCore's Cash Conversion Cycle falls into.


;
;

electroCore Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

electroCore's Cash Conversion Cycle for the fiscal year that ended in Dec. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=15.1+184.96-192.38
=7.68

electroCore's Cash Conversion Cycle for the quarter that ended in Dec. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=12.43+166.71-140.82
=38.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


electroCore  (NAS:ECOR) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


electroCore Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of electroCore's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


electroCore Business Description

Traded in Other Exchanges
N/A
Address
200 Forge Way, Suite 205, Rockaway, NJ, USA, 07866
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
Executives
Daniel S Goldberger director, officer: Chief Executive Officer 24 CARPENTER ROAD, CHESTER NY 10918
Thomas J. Errico director, 10 percent owner 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 97920
John P Gandolfo director 62 TERRACE ROAD, WAYNE NJ 07470
Joseph P Errico director, 10 percent owner, officer: See Remarks 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Trevor J Moody director 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Julie Ann Goldstein director 205 FORGE WAY, ROCKAWAY NJ 07866
Patricia Wilber director 205 FORGE WAY, SUITE 205, ROCKAWAY NJ 07866
Brian M Posner officer: Chief Financial Officer 1590 REED ROAD, PENNINGTON NJ 08534
Tullis James L L director 100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Thomas M Patton director C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
F Peter Cuneo director 10 EAST 40TH ST, NEW YORK NY 10016
Stephen Ondra director 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Nicholas Colucci director 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Michael G Atieh director MERCK MEDCO MANAGED CARE INC, 100 SUMMIT AVE, MONTVALE NJ 07645
Carrie Smith Cox director SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033